Dan Leonard
Stock Analyst at UBS
(3.14)
# 1,171
Out of 4,711 analysts
273
Total ratings
54.67%
Success rate
8.52%
Average return
Main Sectors:
Stocks Rated by Dan Leonard
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BRKR Bruker | Assumes: Neutral | $102 → $66 | $57.00 | +15.79% | 10 | Dec 10, 2024 | |
| TXG 10x Genomics | Maintains: Neutral | $25 → $20 | $14.04 | +42.45% | 3 | Oct 30, 2024 | |
| DHR Danaher | Maintains: Buy | $309 → $305 | $228.55 | +33.45% | 16 | Oct 23, 2024 | |
| CYRX Cryoport | Maintains: Neutral | $7 → $9 | $7.86 | +14.50% | 2 | Oct 18, 2024 | |
| MEDP Medpace Holdings | Downgrades: Neutral | $420 → $350 | $337.28 | +3.77% | 1 | Sep 27, 2024 | |
| CERT Certara | Upgrades: Buy | $16 | $10.71 | +49.39% | 9 | Sep 27, 2024 | |
| GH Guardant Health | Maintains: Buy | $32 → $40 | $31.67 | +26.30% | 8 | Aug 21, 2024 | |
| IQV IQVIA Holdings | Maintains: Buy | $295 → $300 | $197.27 | +52.08% | 12 | Jul 23, 2024 | |
| BIO Bio-Rad Laboratories | Maintains: Buy | $420 → $385 | $327.47 | +17.57% | 19 | May 8, 2024 | |
| BIO.B Bio-Rad Laboratories | Maintains: Buy | $420 → $385 | $325.85 | +18.15% | 19 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $105 → $125 | $112.56 | +11.05% | 1 | Jan 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $80 | $73.17 | +9.33% | 10 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $18.34 | +90.84% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $160 → $150 | $134.51 | +11.52% | 21 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $200 | $136.02 | +47.04% | 16 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $11 | $5.37 | +104.84% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $70 | $161.88 | -56.76% | 7 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $90 | $59.40 | +51.52% | 9 | Aug 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $24 | $21.21 | +13.15% | 6 | Jul 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $620 | $524.05 | +18.31% | 13 | Jul 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $260 → $255 | $185.77 | +37.27% | 5 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $7 | $6.39 | +9.55% | 2 | Feb 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $345 | $368.16 | -6.29% | 12 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $260 | $207.51 | +25.30% | 5 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $160 → $145 | $153.10 | -5.29% | 10 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $90 | $71.65 | +25.61% | 12 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $60 → $62 | $44.67 | +38.35% | 3 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $330 → $340 | $228.61 | +48.72% | 11 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $20.56 | +16.73% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,350 → $1,500 | $1,230.74 | +21.88% | 8 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $45 → $35 | $13.36 | +161.98% | 12 | Aug 14, 2019 |
Bruker
Dec 10, 2024
Assumes: Neutral
Price Target: $102 → $66
Current: $57.00
Upside: +15.79%
10x Genomics
Oct 30, 2024
Maintains: Neutral
Price Target: $25 → $20
Current: $14.04
Upside: +42.45%
Danaher
Oct 23, 2024
Maintains: Buy
Price Target: $309 → $305
Current: $228.55
Upside: +33.45%
Cryoport
Oct 18, 2024
Maintains: Neutral
Price Target: $7 → $9
Current: $7.86
Upside: +14.50%
Medpace Holdings
Sep 27, 2024
Downgrades: Neutral
Price Target: $420 → $350
Current: $337.28
Upside: +3.77%
Certara
Sep 27, 2024
Upgrades: Buy
Price Target: $16
Current: $10.71
Upside: +49.39%
Guardant Health
Aug 21, 2024
Maintains: Buy
Price Target: $32 → $40
Current: $31.67
Upside: +26.30%
IQVIA Holdings
Jul 23, 2024
Maintains: Buy
Price Target: $295 → $300
Current: $197.27
Upside: +52.08%
Bio-Rad Laboratories
May 8, 2024
Maintains: Buy
Price Target: $420 → $385
Current: $327.47
Upside: +17.57%
Bio-Rad Laboratories
May 8, 2024
Maintains: Buy
Price Target: $420 → $385
Current: $325.85
Upside: +18.15%
Jan 16, 2024
Downgrades: Neutral
Price Target: $105 → $125
Current: $112.56
Upside: +11.05%
Dec 7, 2023
Initiates: Buy
Price Target: $80
Current: $73.17
Upside: +9.33%
Dec 7, 2023
Initiates: Neutral
Price Target: $35
Current: $18.34
Upside: +90.84%
Aug 16, 2023
Maintains: Outperform
Price Target: $160 → $150
Current: $134.51
Upside: +11.52%
Aug 10, 2023
Maintains: Neutral
Price Target: $225 → $200
Current: $136.02
Upside: +47.04%
Aug 8, 2023
Maintains: Neutral
Price Target: $14 → $11
Current: $5.37
Upside: +104.84%
Aug 4, 2023
Reiterates: Outperform
Price Target: $70
Current: $161.88
Upside: -56.76%
Aug 2, 2023
Maintains: Neutral
Price Target: $75 → $90
Current: $59.40
Upside: +51.52%
Jul 31, 2023
Reiterates: Neutral
Price Target: $24
Current: $21.21
Upside: +13.15%
Jul 13, 2023
Upgrades: Outperform
Price Target: $620
Current: $524.05
Upside: +18.31%
May 12, 2023
Maintains: Outperform
Price Target: $260 → $255
Current: $185.77
Upside: +37.27%
Feb 15, 2023
Reiterates: Underperform
Price Target: $7
Current: $6.39
Upside: +9.55%
Aug 25, 2022
Initiates: Neutral
Price Target: $345
Current: $368.16
Upside: -6.29%
Aug 25, 2022
Initiates: Neutral
Price Target: $260
Current: $207.51
Upside: +25.30%
Feb 4, 2022
Maintains: Equal-Weight
Price Target: $160 → $145
Current: $153.10
Upside: -5.29%
Feb 3, 2022
Maintains: Overweight
Price Target: $95 → $90
Current: $71.65
Upside: +25.61%
Dec 14, 2021
Maintains: Equal-Weight
Price Target: $60 → $62
Current: $44.67
Upside: +38.35%
Dec 14, 2021
Maintains: Overweight
Price Target: $330 → $340
Current: $228.61
Upside: +48.72%
Aug 10, 2021
Initiates: Overweight
Price Target: $24
Current: $20.56
Upside: +16.73%
Jul 30, 2021
Maintains: Equal-Weight
Price Target: $1,350 → $1,500
Current: $1,230.74
Upside: +21.88%
Aug 14, 2019
Maintains: Hold
Price Target: $45 → $35
Current: $13.36
Upside: +161.98%